Analysis of the difference between entrectinib and whether it is a domestic drug or an imported drug

Entrectinib is a targeted drug targeting NTRK fusion genes and ROS1-positive tumors, and is widely used in the treatment of a variety of solid tumors. Currently, only imported original drugs of entrectinib are available in the domestic market, and there are no domestic generic drugs on the market. This is mainly due to high drug patent protection and technical barriers. Domestic pharmaceutical companies have not yet obtained relevant production and sales licenses, and patients can only purchase imported versions through formal channels.

Imported entrectinib was developed by a well-known international pharmaceutical company and has undergone strict clinical trials and regulatory approvals to ensure reliable efficacy and safety. It enters the domestic market through formal import channels, ensuring the quality and stable supply of medicines. Despite this, the relatively high price of imported drugs has put great financial pressure on some patients, especially when medical insurance is not fully covered.

Currently, there are no domestic substitutes for entrectinib in China, which limits patients’ choices in terms of price and purchasing channels. In order to reduce their financial burden, some patients will choose to purchase imported drugs through overseas channels. However, this involves certain legal risks and drug authenticity issues, so extra caution is required. When doctors formulate treatment plans for patients, they usually give reasonable suggestions based on the patient's financial status and drug availability.

Overall, entrectinib is currently an imported original drug in China, and the domestic version has not yet been launched. With the continuous advancement of domestic biomedical technology and the end of patent periods, it is expected that domestic generic drugs will emerge in the future, thereby further reducing patients' medication costs and improving drug accessibility. This will also bring new hope for precise targeted therapy to more patients.

Reference: https://go.drugbank.com/drugs/